The pT1a and pT1b category subdivision in renal cell carcinoma: Is it reflected by differences in tumour biology?

BJU International

Volumn 95, Issue 3, 2005, Pages 310-314

  Langner, Cord ^a   Ratschek, Manfred ^a   Rehak, Peter ^a   Tsybrovskyy, Oleksiy ^a   Zigeuner, Richard ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Immunohistochemistry; Pathology; Renal cell carcinoma; Tissue microarray; TNM; Tumour category

Indexed keywords

BIOLOGICAL MARKER; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MUCIN 1; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLEAR CELL CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 14144249315     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05289.x     Document Type: Article

References (23)

1. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma. impact on tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999; 162: 1930-3
2. Kinouchi T, Saiki S, Meguro N et al. Impact of tumor size on the clinical outcomes of patients with Robson stage I renal cell carcinoma. Cancer 1999; 85: 689-95
3. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000; 163: 442-5
4. Zisman A, Pantuck AJ, Chao D et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7cm better correlates with clinical outcome. J Urol 2001; 166: 54-8
5. Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 2002; 59: 532-7
6. Guinan P, Sobin LH, Algaba F et al. TNM staging of renal cell carcinoma. Workgroup 3. Cancer 1997; 80: 992-3
7. Sobin LH, Wittekind C eds. TNM. Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, Inc., 2002
8. Eble JN, Togashi K et al. Renal cell carcinoma. In Eble JN, Sauter G, Epstein JI, Sesterhenn IA eds, World Health Organization Classification of Tumours. Pathology and Genetics, Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press 2004: 93-109
9. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63
10. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7
11. Cheville JC, Zincke H, Lohse MC et al. pT1 clear cell renal cell carcinoma. A study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cancer 2002; 94: 2180-4
12. Migita T, Oda Y, Naito S, Tsuneyoshi M. Low expression of p27kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002; 94: 973-9
13. Ben-Izhak O, Lahav-Baratz S, Meretyk S et al. Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27kip1 in prostate cancer. J Urol 2003; 170: 241-5
14. Uchida T, Gao JP, Wang C et al. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002; 59: 615-20
15. Moch H, Sauter G, Gasser TC et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res 1997; 25 (Suppl. 1): S25-S30
16. Lipponen P, Eskelinen M, Syrjanen K. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 1995; 71: 863-7
17. Heicappel R. Cadherins in renal cell carcinoma. Anticancer Res 1999; 19: 1501-4
18. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod Pathol 2004; 17: 180-8
19. Parker AS, Cheville JC, Lohse C, Cerhan JR, Blute ML. Expression of insulin-like growth factor-I receptor and survival in patients with clear cell renal cell carcinoma. J Urol 2003; 170: 420-4
20. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl. 4): S9-S15
21. Uhlmann DL, Nguyen P, Manivel JC et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1995; 1: 913-20
22. Moch H, Sauter G, Buchholz N et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 1997; 28: 1255-9
23. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Am J Clin Pathol 2000; 113: 374-82